GHK-Cu (50mg) + BPC-157 (10mg) + TB-500 (10mg) + KPV (10mg) KLOW is an advanced peptide blend formulated for research exploring cellular regeneration, inflammation resolution, and dermal repair. Featuring four distinct peptides—GHK-Cu, BPC-157, TB-500, and KPV—this combination is designed for synergistic applications in experimental models of tissue healing, skin biology, and immune modulation.
GHK-Cu is studied for its role in skin regeneration and collagen synthesis. BPC-157 is known for supporting tissue repair, angiogenesis, and cellular protection. TB-500 contributes through actin modulation and enhanced cell migration, while KPV, a melanocortin fragment, has demonstrated anti-inflammatory potential in models of immune dysregulation.
Together, this blend represents a multifaceted approach for researchers studying accelerated wound repair, epithelial recovery, and localized inflammation in skin and connective tissue.
The KLOW Blend is an advanced research formulation that unites four unique peptides GHK-Cu, BPC-157, TB-500, and KPV into a singular, versatile compound. This blend is intended for scientific studies requiring multi-pathway interactions in models of regeneration, inflammation, and epithelial response.
GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma and tissues. It has been widely studied for its role in cellular signaling, tissue repair, and gene modulation. Research has shown that GHK-Cu may activate regenerative pathways in fibroblasts, endothelial cells, and skin tissues, making it of interest in aging and wound-healing models.
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein sequence. It is extensively studied in rodent models for its potential protective effects on blood vessels, muscles, tendons, and the gastrointestinal tract. It may play a role in angiogenesis and cellular repair mechanisms, especially in studies involving nitric oxide pathways.
TB-500 is a synthetic version of a segment of thymosin beta-4. It is recognized for its actin-binding properties and its ability to influence cell migration and wound repair. In laboratory settings, TB-500 is often used to investigate soft tissue dynamics and recovery in muscle or vascular tissues.
KPV, or Lysine-Proline-Valine, is a short peptide fragment studied for its anti-inflammatory and immune-regulating properties. Derived from alpha-MSH, KPV is non-pigmentary but retains the immunosuppressive capabilities of its parent compound. Researchers have explored its potential in models of skin inflammation, gut disorders, and epithelial recovery.
The KLOW Blend delivers these peptides in a single vial, reducing complexity and providing a reliable platform for multi-target research studies. Each peptide contributes distinct biological effects, offering researchers a unique opportunity to explore synergistic or additive mechanisms in one cohesive experiment.
Research & References:
The KLOW Blend combines four peptides with distinct biological profiles, making it a valuable tool for multi-dimensional research. Each component has been independently studied for its influence on specific biological pathways, and together they offer an integrative approach for examining tissue recovery, immune response, and cellular signaling.
GHK-Cu has been the subject of numerous studies for its ability to stimulate collagen production, regulate inflammation, and act as a gene modulator. In vitro research has shown that it can activate over 30% of human genes involved in tissue repair, oxidative stress response, and immune function. Its binding to copper ions enhances its regenerative effects, particularly in dermal and vascular models.
BPC-157 is often studied in research models involving musculoskeletal trauma, GI tract injury, and neurovascular repair. It has demonstrated an ability to enhance nitric oxide signaling, upregulate angiogenic factors, and protect endothelial cells from oxidative damage.
TB-500 supports actin upregulation, a key process in cellular movement and structural repair. Studies have examined its role in tendon healing, cardiac repair, and angiogenesis, particularly in contexts where tissue damage limits recovery.
KPV is increasingly researched for its immunomodulatory effects. As a melanocortin receptor agonist fragment, it may inhibit pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in cellular and animal studies. Its ability to reduce inflammation without melanotropic activity makes it a candidate for skin, gut, and systemic immune research.
The combined use of these peptides in one formulation allows researchers to evaluate cumulative effects on healing, regeneration, and immune balance. This is especially relevant in studies involving epithelial injury, chronic inflammation, or multi-tissue repair. The KLOW Blend provides a comprehensive experimental tool for scientists investigating complex biological processes with interrelated signaling pathways.
- T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015.
- Chest. 2006 Nov;130(5):1433-40. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Rubin BK1, Kater AP, Goldstein AL.
- L. Pickart, J. M. Vasquez-Soltero, and A. Margolina, “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration,” BioMed Res. Int., vol. 2015, p. 648108, 2015. [BioMed Research International]
- K. S. de Souza et al., “Improved cutaneous wound healing after intraperitoneal injection of alpha-melanocyte-stimulating hormone,” Exp. Dermatol., vol. 24, no. 3, pp. 198–203, Mar. 2015, doi: 10.1111/exd.12609.
- C. Lonati et al., “Modulatory effects of NDP-MSH in the regenerating liver after partial hepatectomy in rats,” Peptides, vol. 50, pp. 145–152, Dec. 2013, doi: 10.1016/j.peptides.2013.10.014.
- G. Colombo et al., “Gene expression profiling reveals multiple protective influences of the peptide alpha-melanocyte-stimulating hormone in experimental heart transplantation,” J. Immunol. Baltim. Md 1950, vol. 175, no. 5, pp. 3391–3401, Sep. 2005, doi: 10.4049/jimmunol.175.5.3391.
- G. Colombo et al., “Production and effects of alpha-melanocyte-stimulating hormone during acute lung injury,” Shock Augusta Ga, vol. 27, no. 3, pp. 326–333, Mar. 2007, doi: 10.1097/01.shk.0000239764.80033.7e.
- M. Schiller et al., “Human Dermal Fibroblasts Express Prohormone Convertases 1 and 2 and Produce Proopiomelanocortin-Derived Peptides,” J. Invest. Dermatol., vol. 117, no. 2, pp. 227–235, Aug. 2001, doi: 10.1046/j.0022-202x.2001.01412.x.
- T. Brzoska, M. Böhm, A. Lügering, K. Loser, and T. A. Luger, “Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore,” Adv. Exp. Med. Biol., vol. 681, pp. 107–116, 2010, doi: 10.1007/978-1-4419-6354-3_8.
- S. J. Getting, H. B. Schiöth, and M. Perretti, “Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides,” J. Pharmacol. Exp. Ther., vol. 306, no. 2, pp. 631–637, Aug. 2003, doi: 10.1124/jpet.103.051623.
- K. Pawar, C. S. Kolli, V. K. Rangari, and R. J. Babu, “Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin,” J. Pharm. Sci., vol. 106, no. 7, pp. 1814–1820, Jul. 2017, doi: 10.1016/j.xphs.2017.03.017.
